publication . Article . Conference object . 2018

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

Hans Lilja; Hans Lilja; Lynn Greenhalgh; Gad Rennert; Kate Richardson; Kate Richardson; Alison Falconer; Eitan Friedman; Eitan Friedman; Wendy A. G. van Zelst-Stams; ...
Open Access
  • Published: 23 Jan 2018
Abstract
This research is coordinated by the Institute of Cancer Research, London, UK and is supported by grants from Cancer Research UK (Grant references (C5047/A21332, C5047/A13232 and C5047/A17528) and The Ronald and Rita McAulay Foundation. Mr and Mrs Jack Baker for the study in NorthShore University HealthSystem, Evanston, Illinois and Myriad Genetics Laboratory, Salt Lake City, Utah, for providing research BRCA testing rates for NorthShore University HealthSystem participants. We acknowledge funding from the NIHR to the Biomedical Research Center at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, at Central Manchester Foundation Trust a...
Subjects
Medical Subject Headings: urologic and male genital diseases
free text keywords: Genetics & Genomics, prostate cancer, genetic predisposition, predictive model, PSA velocity, BRCA1, BRCA2, Science & Technology, Life Sciences & Biomedicine, Oncology, BRCA2 MUTATION CARRIERS, RISK, CURABILITY, INCREASE, WINDOW, IMPACT, DEATH, Adult, Aged, BRCA1 Protein, BRCA2 Protein, Early Detection of Cancer, Genetic Predisposition to Disease, Germ-Line Mutation, Humans, Kallikreins, Logistic Models, Male, Middle Aged, Neoplasm Grading, Prostate-Specific Antigen, Prostatic Neoplasms, IMPACT study collaborators, 1112 Oncology and Carcinogenesis, 1117 Public Health and Health Services, Oncology & Carcinogenesis, Journal Article, Krabbamein, Blöðruhálskirtilskrabbamein, Erfðarannsóknir, b_open_article_in_toll_access_journal, Corrigendum, Cancer Research, medicine.medical_specialty, medicine, medicine.disease, Proportional hazards model, Prostate biopsy, medicine.diagnostic_test, Cancer, Internal medicine, Prostate cancer screening, business.industry, business
Funded by
NIH| MOUSE GENETICS
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
Communities
Agricultural and Food Sciences
31 references, page 1 of 3

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Maehle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramo´n y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E. IMPACT CollaboratorsMoss S, Eeles RA (2014) Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT Study. Eur Urol 66: 489-499.

Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W (2005) Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 64: 240-245. [OpenAIRE]

Bratt O, Loman N (2015) Clinical management of prostate cancer in men with BRCA mutations. Eur Urol 68: 194-195. [OpenAIRE]

Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310-1316.

Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220. [OpenAIRE]

Carter HB, Kettermann A, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98: 1521-1527. [OpenAIRE]

Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ (2007) Prostate-specific antigen velocity risk count assessment: a new concept for detection of lifethreatening prostate cancer during window of curability. Urol 70: 685-690. [OpenAIRE]

Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R, Ardern-Jones A, Ellis S, Frost D, Peock S, Evans DG, Tischkowitz M, Cole T, Davidson R, Eccles D, Brewer C, Douglas F, Porteous ME, Donaldson A, Dorkins H, Izatt L, Cook J, Hodgson S, Kennedy MJ, Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z, Eeles R (2013) Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31: 1748-1757.

Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, Govindasami K, Guy M, Ellis S, Frost D, Bancroft E, Cole T, Tischkowitz M, Kennedy MJ, Eason J, Brewer C, Evans DG, Davidson R, Eccles D, Porteous ME, Douglas F, Adlard J, Donaldson A, Antoniou AC, Kote-Jarai Z, Easton DF, Olmos D, Eeles R (2015) Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol 68: 186-193.

D'Amico AV, Chen MH, Roehl KA, Catalona WJ (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125-135. [OpenAIRE]

D'Amico AV, Renshaw AA, Sussman B, Chen MH (2005) Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294: 440-447.

Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA. UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology (2010) Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 103: 918-924.

Eeles R, Goh C, Castro E, Bancroft E, Guy M, Al Olama AA, Easton D, Kote-Jarai Z (2014) The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 11: 18-31.

Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K (2010) Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 16: 2115-2121.

Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, Greene MH, Maslansky B, Fischbein A, Gruber SB, Rennert G, Ronchetti RD, Hewitt SM, Struewing JP, Iscovich J (2003) A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 40: 787-792. [OpenAIRE]

31 references, page 1 of 3
Any information missing or wrong?Report an Issue